|
|
||||||||
induced Sickle RBC Retention in Retina by a VLA-4 Antagonist
1 From the Wilmer Ophthalmological Institute, Johns Hopkins Hospital, Baltimore, Maryland; 2 Texas Biotechnology Corp., Houston, Texas; 3 Department of Immunology, University of Texas, Houston; and 4 Division of Hematology, Albert Einstein College of Medicine, Bronx, New York.
PURPOSE. Patients with sickle cell disease have elevated circulating
levels of cytokines including tumor necrosis factor (TNF)
. TNF-
stimulates expression by endothelial cells of adhesion molecules,
including vascular cell adhesion molecule (VCAM) 1. Others have
demonstrated that VLA-4 (
4ß1), a ligand
for VCAM-1 or fibronectin, is present on a fraction of sickle
reticulocytes. The intent of this study was to determine, using a rat
model, if TNF-
increases retention of sickle erythrocytes in retina
and if that retention can be inhibited.
METHODS. TNF-
was given intraperitoneally to rats 5 hours before IV
administration of FITC-labeled, density-separated sickle erythrocytes.
After 5 minutes, rats were exsanguinated, and retinas were excised and
incubated for ADPase activity, permitting the determination of the
number and location of retained cells.
RESULTS. TNF-
caused a three- to fourfold increase in retention of sickle
erythrocytes in retinal capillaries (P < 0.05) but
not of normal human erythrocytes. Preincubation of sickle erythrocytes
with TBC772, a peptide that blocks the binding of
4ß1 and
4ß7,
or a monoclonal antibody against VLA-4 (19H8), significantly inhibited
the TNF-
induced retention (P
0.02), whereas
a control cyclic peptide and antibody had no effect. IV TBC772 also
inhibited sickle erythrocyte retention (P = 0.01).
Two intravenously administered anti-fibronectin antibodies inhibited
sickle cell retention as well, but an anti-rat VCAM-1 antibody did not
inhibit retention.
CONCLUSIONS. The authors conclude that TNF-
stimulates retention of sickle
erythrocytes in the retinal vasculature. This increased retention can
be blocked by a VLA-4 antagonist, suggesting that the cells retained
after cytokine stimulation are reticulocytes. The counter-receptor for
VLA-4 in this rat retina model appears to be fibronectin and not
VCAM-1, based on data obtained using antibodies against these
molecules.
This article has been cited by other articles:
![]() |
M. J. Telen Role of Adhesion Molecules and Vascular Endothelium in the Pathogenesis of Sickle Cell Disease Hematology, January 1, 2007; 2007(1): 84 - 90. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. G. Woodside, R. M. Kram, J. S. Mitchell, T. Belsom, M. J. Billard, B. W. McIntyre, and P. Vanderslice Contrasting Roles for Domain 4 of VCAM-1 in the Regulation of Cell Adhesion and Soluble VCAM-1 Binding to Integrin {alpha}4beta1. J. Immunol., April 15, 2006; 176(8): 5041 - 5049. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. H. Embury, N. M. Matsui, S. Ramanujam, T. N. Mayadas, C. T. Noguchi, B. A. Diwan, N. Mohandas, and A. T. W. Cheung The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo Blood, November 15, 2004; 104(10): 3378 - 3385. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Holtzclaw, D. Jack, S. M. Aguayo, J. R. Eckman, J. Roman, and L. L. Hsu Enhanced Pulmonary and Systemic Response to Endotoxin in Transgenic Sickle Mice Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 687 - 695. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wei, J. M. Runnels, and C. P. Lin Selective Uptake of Indocyanine Green by Reticulocytes in Circulation Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4489 - 4496. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Matsui, A. Varki, and S. H. Embury Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin Blood, November 15, 2002; 100(10): 3790 - 3796. [Abstract] [Full Text] [PDF] |
||||
![]() |
M K. Mathews, D S McLeod, C Merges, J Cao, and G A Lutty Neutrophils and leucocyte adhesion molecules in sickle cell retinopathy Br. J. Ophthalmol., June 1, 2002; 86(6): 684 - 690. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |